TY - JOUR
T1 - Medication risk-taking behavior in functional dyspepsia patients
AU - Lacy, Brian E.
AU - Yu, Jerry
AU - Crowell, Michael D.
N1 - Funding Information:
Guarantor of the article: Brian E. Lacy, PhD, MD. Specific author contributions: The study was designed and implemented by Lacy, Crowell and Yu. Mailing of the survey and data collection and data input were performed by Lacy and Yu. Statistical analysis was performed by Crowell. The manuscript was written by Lacy, Crowell and Yu. All authors contributed to the editing and final approval of the manuscript. Financial support: No funding was provided for this study. Potential competing interests: No author has any conflict of interest to disclose with regard to this study.
PY - 2015/1/1
Y1 - 2015/1/1
N2 - Objectives: No medication is approved for the treatment of functional dyspepsia (FD). The risks that patients would be willing to take to cure their FD symptoms are unknown. Methods: FD patients (Rome III criteria) were mailed a questionnaire that assessed demographics, medication use, and prior medication adverse events. Scales to measure FD severity, quality of life, anxiety, depression, impulsiveness, and risk-taking behavior were included. A standard gamble (SG) evaluated willingness to take risks associated with a theoretical FD medication. Data were analyzed using simple descriptive statistics. Results: One hundred and fourteen responses were analyzed (54.5% response rate). The mean age of the patients was 49.2 years; 84% were women and 96% were white. The mean duration of symptoms was 8.2 years (range 1-38 years). The most bothersome symptom was upper abdominal discomfort (25%), followed by upper abdominal pain (22%) and bloating (15%). Forty percent of respondents rated their FD symptoms as moderate and 31% as mild. Forty-six percent reported a side effect from a prescription medication used to treat FD. When asked about a hypothetical medication that could cure their FD symptoms, 49% of respondents reported that they would accept a mean 12.7% risk of sudden death for a 99% chance of cure. Conclusions: This prospective study suggests that FD patients are surprisingly willing to take significant risks with a hypothetical medication to cure their symptoms. To counsel patients effectively and assist in the development of informed, preference-based decisions regarding medication therapy, physicians need to elicit and understand FD patients' risk adversity.
AB - Objectives: No medication is approved for the treatment of functional dyspepsia (FD). The risks that patients would be willing to take to cure their FD symptoms are unknown. Methods: FD patients (Rome III criteria) were mailed a questionnaire that assessed demographics, medication use, and prior medication adverse events. Scales to measure FD severity, quality of life, anxiety, depression, impulsiveness, and risk-taking behavior were included. A standard gamble (SG) evaluated willingness to take risks associated with a theoretical FD medication. Data were analyzed using simple descriptive statistics. Results: One hundred and fourteen responses were analyzed (54.5% response rate). The mean age of the patients was 49.2 years; 84% were women and 96% were white. The mean duration of symptoms was 8.2 years (range 1-38 years). The most bothersome symptom was upper abdominal discomfort (25%), followed by upper abdominal pain (22%) and bloating (15%). Forty percent of respondents rated their FD symptoms as moderate and 31% as mild. Forty-six percent reported a side effect from a prescription medication used to treat FD. When asked about a hypothetical medication that could cure their FD symptoms, 49% of respondents reported that they would accept a mean 12.7% risk of sudden death for a 99% chance of cure. Conclusions: This prospective study suggests that FD patients are surprisingly willing to take significant risks with a hypothetical medication to cure their symptoms. To counsel patients effectively and assist in the development of informed, preference-based decisions regarding medication therapy, physicians need to elicit and understand FD patients' risk adversity.
UR - http://www.scopus.com/inward/record.url?scp=84927651995&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84927651995&partnerID=8YFLogxK
U2 - 10.1038/ctg.2014.18
DO - 10.1038/ctg.2014.18
M3 - Article
AN - SCOPUS:84927651995
VL - 6
JO - Clinical and Translational Gastroenterology
JF - Clinical and Translational Gastroenterology
SN - 2155-384X
IS - 1
M1 - e69
ER -